Pharsight

Drugs that contain Dolutegravir Sodium

1. Tivicay patents expiration

TIVICAY's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8129385 VIIV HLTHCARE Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness
Oct, 2027

(3 years from now)

US9242986 VIIV HLTHCARE Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates
Dec, 2029

(5 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8129385

(Pediatric)

VIIV HLTHCARE Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness
Apr, 2028

(4 years from now)

US9242986

(Pediatric)

VIIV HLTHCARE Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates
Jun, 2030

(6 years from now)

Market Authorisation Date: 12 August, 2013

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of TIVICAY before it's drug patent expiration?
More Information on Dosage

TIVICAY family patents

Family Patents

2. Tivicay Pd patents expiration

TIVICAY PD's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8129385 VIIV HLTHCARE Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness
Oct, 2027

(3 years from now)

US9242986 VIIV HLTHCARE Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates
Dec, 2029

(5 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8129385

(Pediatric)

VIIV HLTHCARE Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness
Apr, 2028

(4 years from now)

US9242986

(Pediatric)

VIIV HLTHCARE Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates
Jun, 2030

(6 years from now)

Market Authorisation Date: 12 June, 2020

Treatment: NA

Dosage: TABLET, FOR SUSPENSION;ORAL

How can I launch a generic of TIVICAY PD before it's drug patent expiration?
More Information on Dosage

TIVICAY PD family patents

Family Patents